The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
== External links == CID 16132316 from PubChem – β-endorphin CID 3081525 from PubChem – β-endorphin (1-9) CID 133304 from PubChem – β-endorphin (2-9) β-endorphin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Enterohepatic circulation === Research by Aarons has focused on enterohepatic cycling (EHC) which refers to the process whereby a drug goes through the liver and biliary tract for excretion and is released into the small intestine, where it can be reabsorbed back into circulation and subsequently returned to the liver. This can cause liver damage and the half-life and duration of a drug to be increased. Aarons and his team stressed that knowing the extent of EHC is invaluable in deciding whether or not the in vitro characteristics of a drug - i.e. those taking place outside of a living organism - will have any effect on the overall process of absorption in vivo, or when it is taking place inside the organism. Aarons had earlier been involved in research on the area under the curve (AUC). This is a pharmacokinetic statistic used to describe the total exposure to a drug - specifically the concentration of a drug in body fluids such as blood - and is useful because it gives insight into the extent of exposure to a drug and its clearance rate from the body. The research was seen as important in the "design of sampling protocols for accurate determination of AUC(0– ∞) for drugs subject to enterohepatic cycling."
For a given acid or base in water, pKa + pKb = pKw, the self-ionization constant of water. The association constant for the formation of a supramolecular complex may be denoted as Ka; in such cases "a" stands for "association", not "acid". For polyprotic acids, the numbering of stepwise association constants is the reverse of the numbering of the dissociation constants. For example, for phosphoric acid (details in the polyprotic acids section below):
According to Jay Garfield, in the first chapter, Nāgārjuna argues against a reified view of causality which sees dependent origination in terms of substantial powers (kriyā) of causation (hetu) that phenomena have as part of their intrinsic nature (svabhāva). Instead, Nāgārjuna sees dependent origination as a series of conditional relationships (pratyaya) that are merely nominal designations and "explanatorily useful regularities". According to Nāgārjuna, if something could exist inherently or essentially from its own side (and thus have its own inherent causal powers), change and dependent arising would be impossible. Nāgārjuna states that "if things did not exist without essence, the phrase, "when this exists so this will be," would not be acceptable." Jan Westerhoff notes that Nāgārjuna argues that cause and effect are "neither identical nor different nor related as part and whole, they are neither successive, nor simultaneous, nor overlapping." Westerhoff states that Nāgārjuna thinks all conceptual frameworks of causality that make use of such ideas are based on a mistaken presupposition which is that "cause and effect exist with their own svabhāva". Westerhoff further argues that for Nāgārjuna, causes and effects are both dependent on one another (conceptually and existentially) and neither one can exist independently. As such, he rejects four ways that something could be causally produced: by itself, by something else, by both, by nothing at all.
== Adverse effects == The most common adverse side effects of clonidine are dry mouth and sedation. Many side effects are dose-related and tend to diminish with tolerance that develops from continued use. For the same reason that clonidine has efficacy for treating hypertension, hypotension (i.e., low blood pressure) and bradycardia (i.e., slow heart rate) are predictable dose-dependent effects. However, with overdose in children, the degree of central nervous system depression does not clearly correlate with the ingested dose.
Sources: en.wikipedia.org
The batmen were skilled at presenting and maintaining several police uniform 'dress orders' worn throughout any given day, all of which were expected to be immaculate at all times. The responsibilities of these Caucasian police officers, once trained, were broadly the same as those of UK police officers. Black officers engaged in operational police work worked alongside their white colleagues on investigations and patrols, necessarily acting as interpreters with the indigenous population, as well as patrolling alone and conducting their own crime investigations or as otherwise directed. Black "ground coverage" officers acted as undercover plainclothes intelligence gatherers in both rural and urban areas. A district (rural) police station with a strength of anything from a dozen to forty personnel was often required to 'fly the flag' over an area comprising several hundred sq. kilometres. On 18 December 1978, Equitation Squad 14/78–the first multi-racial recruit squad-began training at Morris Depot in Salisbury (now Harare). Prior to this date, Black recruits were trained at Tomlinson Depot, while White officers were trained at Morris Depot. Included in this historic intake was Patrol Officer Sinclair Roberts, the first mixed-race Police Officer accepted to the Force, 89 years after it was founded.
By the spring of 1917, the War was dragging on towards its fourth year, and Zita's brother Prince Sixtus of Bourbon-Parma, a serving officer in the Belgian Army, was a main mover behind a plan for Austria-Hungary to make a separate peace with France. Charles initiated contact with Sixtus through contacts in neutral Switzerland, and Zita wrote a letter inviting him to Vienna. Zita's mother, Maria Antonia, delivered the letter in person. Sixtus arrived with conditions for talks which had been agreed with the French – the restoration to France of Alsace-Lorraine (annexed by Germany after the Franco-Prussian War in 1870); restoration of the independence of Belgium; independence for the kingdom of Serbia; and the handover of Constantinople to Russia. Charles agreed, in principle, to the first three points and wrote a letter to Sixtus dated 25 March 1917 which sent "the secret and unofficial message" to the President of France that "I will use all means and all my personal influence". This attempt at dynastic diplomacy eventually foundered. Germany refused to negotiate over Alsace-Lorraine, and, seeing a Russian collapse on the horizon, was loath to give up the war. Sixtus continued his efforts, even meeting David Lloyd George in London about Italy's territorial demands on Austria in the 1915 Treaty of London, but the Prime Minister could not persuade his generals that Britain should make peace with Austria. Zita managed a personal achievement during this time by stopping the German plans to send airplanes to bomb the home of the King and Queen of Belgium on their name days.
Feringa and co-workers used this approach in their design of a molecule that can repeatably perform 360° rotation. The full rotation of this molecular motor takes place in four stages. In stages A and C rotation of the aryl moiety is restricted, although helix inversion is possible. In stages B and D the aryl can rotate with respect to the naphthalene with steric interactions preventing the aryl from passing the naphthalene. The rotary cycle consists of four chemically induced steps which realize the conversion of one stage into the next. Steps 1 and 3 are asymmetric ring opening reactions which make use of a chiral reagent in order to control the direction of the rotation of the aryl. Steps 2 and 4 consist of the deprotection of the phenol, followed by regioselective ring formation.
== Structure == Similar to G protein-coupled receptors (GPCRs), AdipoR1 also possesses 7 transmembrane domains. However, AdipoR1 is orientated oppositely to GPCRs in the membrane (i.e., cytoplasmic N-terminus, extracellular C-terminus) and does not associate with G proteins.
=== Morphology === The morphologic variations in the size, shape, volume, tissue density, pectoral locale, and spacing of the breasts determine their natural shape, appearance, and position on a woman's chest. Breast size and other characteristics do not predict the fat-to-milk-gland ratio or the potential for the woman to nurse an infant. The size and the shape of the breasts are influenced by normal-life hormonal changes (thelarche, menstruation, pregnancy, menopause) and medical conditions (e.g. breast hypertrophy). The shape of the breasts is naturally determined by the support of the suspensory Cooper's ligaments, the underlying muscle and bone structures of the chest, and by the skin envelope. The suspensory ligaments sustain the breast from the clavicle (collarbone) and the clavico-pectoral fascia (collarbone and chest) by traversing and encompassing the fat and milk-gland tissues. The breast is positioned, affixed to, and supported upon the chest wall, while its shape is established and maintained by the skin envelope. In most women, one breast is slightly larger than the other. More obvious and persistent asymmetry in breast size occurs in up to 25% of women. The base of each breast is attached to the chest by the deep fascia over the pectoralis major muscles. The base of the breast is semi-circular, however the shape and position of the breast above the surface is variable. The space between the breast and the pectoralis major muscle, called retromammary space, gives mobility to the breast.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.